Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Songlingxuemaikang Capsule in Low- and Middle-Risk Hypertension
ChiCTR-IPR-17011383Phase 4Completed
- Sponsor
- Xiyuan Hospital
- Start
- Jun 2017
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in essential hypertension comparing Songlingxuemaikang Capsule with Placebo (2 arms). Primary endpoint: 24-hour average blood pressure. Started Jun 2017; status: completed.
02
Drugs
songling xuemaikang
03
Conditions
essential hypertension
Beyond the preview
Go deeper on ChiCTR-IPR-17011383.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-17011383.